Manel Esteller and Pier Paolo Pandolfi
Cancer Discov March 20 2017 DOI:10.1158/2159-8290.CD-16-1292
Cancer research community decries President Trump's proposed reductions in funding for the NIH.
Global HOPE will train providers and establish pediatric oncology networks in sub-Saharan Africa.
Targeted delivery of CAR gene to TRAC locus improves potency of therapeutic T cells.
Consensus reached on how to measure tumor progression for patients taking immune-modulating cancer drugs.
Apoptotic protein spurs release of protumor cytokines.
Second-line treatment with pembrolizumab less toxic and more effective.
Controversial proposal to require renewed consent for future use of deidentified biospecimens dropped.
Transport receptor prevents degradation of critical protein by removing it from cytoplasm.
New funding aimed at confirming and elucidating the biological function of noncoding regions in the human genome.
Expert panel's recommendations aim to standardize molecular biomarker testing and guide use of targeted therapies.
Low-frequency variants thought to cause cancer may be artifacts of sample preparation–induced DNA damage.
Spread of pancreatic cancer cells to distant sites also influenced by glucose metabolism.
Mutations in IDH1/2 impair homologous recombination, present therapeutic opportunity.
Drugs that perturb protein metabolism and stress responses could combat aggressive subpopulations of tumor cells.
Addition of reporter gene enables researchers to track cells' route and efficacy, using PET.
Complete remission seen in two infants given genetically modified T cells from an unmatched donor.
Patients could soon have another first-line option, although many oncologists are looking ahead to alectinib.
Second PD-1–targeting inhibitor in less than a year approved for this disease.
Genomic profiling sorts disease into three categories; uncovers potentially targetable molecular alterations.
Loss of ME2 in frequently deleted SMAD4 locus renders cells vulnerable to silencing of its paralog, ME3.
Building on bench studies, supercomputer simulations aim to illuminate RAS in action on the plasma membrane.
Resistance to BRAF plus MEK inhibitors may be reversible in patients with BRAFV600-mutant melanoma.
Cancer cell–derived C3 is essential for the growth of disseminated cancer cells in the CSF.
T-cell bispecific antibodies (TCB) targeting BCMA or FcRH5 induce T cell–mediated myeloma cell death.
Inhibition of class IIa HDACs with TMP195 promotes a macrophage-dependent reduction in tumor burden.
H3K27M-expressing diffuse intrinsic pontine gliomas (DIPG) are dependent on residual PRC2 activity.
ENL binds acetylated histone 3 to promote oncogenic gene expression and AML cell proliferation.
The substrate binding site in MRP1 contains a positively charged region and a hydrophobic region.
Trastuzumab plus lapatinib achieves the highest response rates in HER2-enriched HER2+ breast tumors.
The MDM2 inhibitor MK-8242 is tolerable in patients with liposarcoma and other advanced solid tumors.
Compound 3144 is a multivalent pan-RAS inhibitor that suppresses tumor growth in vivo.
OnlineFirst articles are published online before they appear in a regular issue of the journal. Cancer Discovery publishes two types of OnlineFirst articles.
OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.
Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.
Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.
When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).
While an article is OnlineFirst, it may be cited as shown in the following example:
Elizabeth A. Platz et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment (April 1, 2011) Cancer Discov, 10.1158/2159-8274.CD-10-0020.
Sign up to be notified each time OnlineFirst articles are posted in Cancer Discovery.